Diagnostics World | Blood-based biomarkers predicting when symptoms of amyotrophic lateral sclerosis (ALS) will emerge are expected to catapult the medical research community forward in the quest to prevent the fatal neurodegenerative disorder. Researchers from the University of Miami Miller School of Medicine have been spearheading the Pre-Symptomatic Familial ALS (Pre-fALS) study collecting longitudinal data and biological samples from people at elevated genetic risk for ALS since the project’s 2007 inception.
